J Pontes1, M Madeira2, C H A Lima3, L L Ogino3, F de Paula Paranhos Neto2, L M C de Mendonça2, M L F Farias2, L Kasuki1,4, M R Gadelha5,6,7,8,9. 1. Neuroendocrinology Research Center, Rio de Janeiro, Brazil. 2. Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 3. Neuropathology and Molecular Genetic Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil. 4. Neuroendocrine Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil. 5. Neuroendocrinology Research Center, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br. 6. Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br. 7. Neuropathology and Molecular Genetic Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br. 8. Neuroendocrine Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil. mgadelha@hucff.ufrj.br. 9. Rua Professor Rodolpho Paulo Rocco, 255, 9° andar, Setor 9F, Sala de Pesquisa em Neuroendocrinologia IIha do Fundão, Rio De Janeiro, 21941-913, Brazil. mgadelha@hucff.ufrj.br.
Abstract
PURPOSE: Acromegaly is a cause of secondary osteoporosis and is associated with increased risk of vertebral fractures (VFs). The influence of exon 3-deleted isoform of growth hormone receptor (d3-GHR) on bone microarchitecture has not been studied in acromegaly. AIM: The aim of this study was to analyze the associations between d3-GHR isoform and bone mineral density (BMD), bone microarchitecture, and VFs in acromegaly patients. METHODS: Consecutive acromegaly patients treated at a single reference center were included. BMD was analyzed using dual-energy X-ray absorptiometry (DXA) and bone microarchitecture was analyzed by high-resolution peripheral quantitative computed tomography (HR-pQCT). The presence of moderate to severe VFs was assessed by thoracic and lumbar X-ray. GHR genotyping was analyzed by PCR, and full-length isoform of GHR (fl-GHR) was represented by a 935-bp fragment and d3-GHR by a 532-bp fragment. RESULTS: Eighty-nine patients were included [56 females; median age at diagnosis: 43 years (17-78)]. Disease was uncontrolled in 63% of patients. At least one d3-GHR allele was present in 60% of patients. Frequency of active disease (p = 0.276) and hypogonadism (p = 1.000) was not different between patients with fl-GHR and those with at least one d3-GHR. There was no difference in any DXA or HR-pQCT parameters between patients with fl-GHR and those with d3-GHR. Significant VFs were observed in 14% of patients, but there was no difference in frequency between patients with fl-GHR and those with at least one d3-GHR allele (p = 0.578). CONCLUSIONS: Presence of d3-GHR was not associated with worse BMD or bone microarchitecture or with higher frequency of significant VFs.
PURPOSE:Acromegaly is a cause of secondary osteoporosis and is associated with increased risk of vertebral fractures (VFs). The influence of exon 3-deleted isoform of growth hormone receptor (d3-GHR) on bone microarchitecture has not been studied in acromegaly. AIM: The aim of this study was to analyze the associations between d3-GHR isoform and bone mineral density (BMD), bone microarchitecture, and VFs in acromegalypatients. METHODS: Consecutive acromegalypatients treated at a single reference center were included. BMD was analyzed using dual-energy X-ray absorptiometry (DXA) and bone microarchitecture was analyzed by high-resolution peripheral quantitative computed tomography (HR-pQCT). The presence of moderate to severe VFs was assessed by thoracic and lumbar X-ray. GHR genotyping was analyzed by PCR, and full-length isoform of GHR (fl-GHR) was represented by a 935-bp fragment and d3-GHR by a 532-bp fragment. RESULTS: Eighty-nine patients were included [56 females; median age at diagnosis: 43 years (17-78)]. Disease was uncontrolled in 63% of patients. At least one d3-GHR allele was present in 60% of patients. Frequency of active disease (p = 0.276) and hypogonadism (p = 1.000) was not different between patients with fl-GHR and those with at least one d3-GHR. There was no difference in any DXA or HR-pQCT parameters between patients with fl-GHR and those with d3-GHR. Significant VFs were observed in 14% of patients, but there was no difference in frequency between patients with fl-GHR and those with at least one d3-GHR allele (p = 0.578). CONCLUSIONS: Presence of d3-GHR was not associated with worse BMD or bone microarchitecture or with higher frequency of significant VFs.
Authors: P J Godowski; D W Leung; L R Meacham; J P Galgani; R Hellmiss; R Keret; P S Rotwein; J S Parks; Z Laron; W I Wood Journal: Proc Natl Acad Sci U S A Date: 1989-10 Impact factor: 11.205
Authors: Paula P B Silva; Fatemeh G Amlashi; Elaine W Yu; Karen J Pulaski-Liebert; Anu V Gerweck; Pouneh K Fazeli; Elizabeth Lawson; Lisa B Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski; Mary Bouxsein; Nicholas A Tritos Journal: Eur J Endocrinol Date: 2017-08-05 Impact factor: 6.664
Authors: M Lunt; D Felsenberg; J Reeve; L Benevolenskaya; J Cannata; J Dequeker; C Dodenhof; J A Falch; P Masaryk; H A Pols; G Poor; D M Reid; C Scheidt-Nave; K Weber; J Varlow; J A Kanis; T W O'Neill; A J Silman Journal: J Bone Miner Res Date: 1997-11 Impact factor: 6.741
Authors: Miguel Madeira; Leonardo Vieira Neto; Francisco de Paula Paranhos Neto; Inayá Corrêa Barbosa Lima; Laura Maria Carvalho de Mendonça; Mônica Roberto Gadelha; Maria Lucia Fleiuss de Farias Journal: J Clin Endocrinol Metab Date: 2013-03-12 Impact factor: 5.958
Authors: Sanne E Franck; Linda Broer; Aart Jan van der Lely; Peter Kamenicky; Ignacio Bernabéu; Elena Malchiodi; Patric J D Delhanty; Fernando Rivadeneira; Sebastian J C M M Neggers Journal: Neuroendocrinology Date: 2016-08-12 Impact factor: 4.914